NCT04322227

Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects

Interventional, Randomized, Double-blind, Placebo-controlled Three-way Crossover Study Investigating the Pharmacodynamic Effects of Two Doses of Foliglurax Using Electroencephalography in Patients With Parkinson's Disease and in Healthy Subjects

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: H. Lundbeck A/S · Industry
• Sex: All
• Age: 50 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate effects of foliglurax on brain wave patterns (electric signals) in healthy subjects and in patients with PD

Detailed description

All Treatment Periods (P1 to P3) consist of 7 days of dosing (D1 to D7) with either: * 10 mg foliglurax bis in die (BID) (treatment A) * 30 mg foliglurax BID (treatment B) * Placebo BID (treatment C)

Conditions

• Parkinson Disease
• Healthy

Interventions

Type	Name	Description
DRUG	Foliglurax 10 mg (treatment A)	Foliglurax 10 mg, (BID) capsules, orally
DRUG	Foliglurax 30 mg (treatment B)	Foliglurax 30 mg, BID capsules, orally
DRUG	Placebo (treatment C)	Placebo, BID capsules, orally

Timeline

• Start date: 2020-01-23
• Primary completion: 2020-05-30
• Completion: 2020-05-30
• First posted: 2020-03-26
• Last updated: 2020-07-07

Locations

1 site across 1 country: France